Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911862 | 0.83 | MEN1 (0.53) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2204177 | 0.82 | MEN1 (0.52) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL15475020 | 0.82 | ALDH1A1 (0.54) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12311929 | 0.81 | MEN1 (0.53) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL21475149 | 0.80 | KDM4E (0.59) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2205189 | 0.80 | SIRT6 (0.58) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14970728 | 0.78 | LTA4H (0.53) | KDM4EALDH1A1MEN1KMT2ALTA4H | |
| Hydrochloric Acid SCHEMBL14966567 | 0.77 | LTA4H (0.52) | KDM4ELTA4H | |
| SCHEMBL12311793 | 0.77 | HRH3 (0.60) | DRD3ALDH1A1SIGMAR1HRH3DRD2 | |
| SCHEMBL13634514 | 0.76 | L3MBTL1 (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | DRD3 3329/4885KDM4E 3392/4885ALDH1A1 4117/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | DRD3 3329/4885KDM4E 3392/4885ALDH1A1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.